News Daily News Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Caitlin E. Cox October 22, 2025
News Daily News Little Pre- and Postmarket Testing for Most Recalled CV Devices Michael O'Riordan September 16, 2024
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for January 2019 Caitlin E. Cox January 31, 2019